Baxter International (BAX)
(Delayed Data from NYSE)
$35.97 USD
-0.94 (-2.55%)
Updated Oct 2, 2024 04:00 PM ET
After-Market: $35.97 0.00 (0.00%) 5:22 PM ET
2-Buy of 5 2
A Value F Growth B Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$35.97 USD
-0.94 (-2.55%)
Updated Oct 2, 2024 04:00 PM ET
After-Market: $35.97 0.00 (0.00%) 5:22 PM ET
2-Buy of 5 2
A Value F Growth B Momentum C VGM
Zacks News
Can Strategic Alliances Aid LabCorp's (LH) Q2 Earnings?
by Zacks Equity Research
LabCorp (LH) is expected to gain traction from a solid LabCorp Diagnostics segment in Q2, courtesy of a favorable price, mix, tuck-in acquisitions and organic volume.
Trump's APAC Focus Puts Spotlight on These 3 MedTech Stocks
by Sreyoshi Mukherjee
Despite the trade war upheaval in Asia, some medical device companies stand strong in the APAC region.
AngioDynamics (ANGO) Misses Q4 Earnings & Revenue Estimates
by Zacks Equity Research
AngioDynamics (ANGO) misses Q4 earnings and revenue estimates; international sales high.
Can International Sales Drive Baxter's (BAX) Q2 Earnings?
by Zacks Equity Research
Baxter's (BAX) Q2 earnings likely to be aided by promising international ventures and acquisitions; cyclophosphamide competition raises concern.
Here's Why You Should Invest in Baxter (BAX) Stock Right Now
by Zacks Equity Research
Baxter's (BAX) raised 2018 guidance and strong international presence make it a lucrative pick.
HRC or BAX: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
HRC vs. BAX: Which Stock Is the Better Value Option?
Stryker or Baxter: Which is a Better Pick for Your Portfolio?
by Zacks Equity Research
Stryker (SYK) and Baxter's (BAX) strong expected growth rates and rising share price make them close contenders in the MedTech industry.
5 Stocks Near 52-Week High: Is More Upside in the Cards?
by Zacks Equity Research
Here are some stocks trading near their 52-week high levels with potential to scale higher.
BSX or BAX: Which is a Better Pick for Your Portfolio Now?
by Zacks Equity Research
After considering various parameters and fundamentals, we help you make a choice between Boston Scientific (BSX) and Baxter (BAX).
Zacks.com highlights: Jazz Pharmaceuticals, Baxter International, Boise Cascade, Insight Enterprises and Comfort Systems USA
by Zacks Equity Research
Zacks.com highlights: Jazz Pharmaceuticals, Baxter International, Boise Cascade, Insight Enterprises and Comfort Systems USA
5 Stocks Near 52-Week High With More Room to Run
by Zacks Equity Research
Here are some stocks trading near their 52-week high levels and still with plenty of room for upside.
Baxter (BAX) Soars to a 52-Week High, Time to Cash Out?
by Zacks Equity Research
Baxter International Inc. is at a 52-week high, but can investors hope for more gains in the future? We take a look at the fundamentals for BAX for clues.
Cooper Companies (COO) Q2 Earnings & Revenues Beat Estimates
by Zacks Equity Research
Cooper (COO) witnesses strong growth across segments and geographies in fiscal Q2.
Here's Why You Should Invest in Baxter International Now
by Zacks Equity Research
Strategic buyouts consistently help Baxter (BAX) gain market traction. Recently, the company completes the consolidation of both RECOTHROM and PREVELEAK.
Zacks.com featured highlights include: Schweitzer-Mauduit, Insight, Baxter, Boise Cascade and Comfort Systems
by Zacks Equity Research
Zacks.com featured highlights include: Schweitzer-Mauduit, Insight, Baxter, Boise Cascade and Comfort Systems
5 Stocks Near 52-Week High With Potential to Scale Higher
by Zacks Equity Research
Here are some stocks trading near their 52-week high levels and still with plenty of room for upside.
US-North Korea Summit Talks Resume: 4 MedTech Stocks to Watch
by Nabaparna Bhattacharya
Here we take a look at four leading MedTech players that are gaining from opportunities in the APAC market
Baxter International (BAX) Hits a 52-Week High, Can the Run Continue?
by Zacks Equity Research
Baxter International Inc. is at a 52-week high, but can investors hope for more gains in the future? We take a look at the fundamentals for BAX for clues.
Baxter International (BAX) Up 3.5% Since Earnings Report: Can It Continue?
by Zacks Equity Research
Baxter International (BAX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Medtronic (MDT) Q4 Earnings Beat on Growth in All Lines
by Zacks Equity Research
All major business groups of Medtronic (MDT) contribute to solid top-line growth at CER, which highlighted sustainability across groups and regions.
BioScrip's Core Business Strong Despite Reimbursement Issues
by Zacks Equity Research
BioScrip (BIOS) consistently advances with its multi-faceted CORE plan to perk up the money matters. However, reimbursement cuts pertaining to 21st century Cures Act might hinder growth in 2018.
Zacks.com highlights: Schweitzer-Mauduit International, Insight Enterprises, Baxter International, Fortinet and Comfort Systems USA
by Zacks Equity Research
Zacks.com highlights: Schweitzer-Mauduit International, Insight Enterprises, Baxter International, Fortinet and Comfort Systems USA
Baxter (BAX) Gets FDA Nod for Spectrum IQ, Secures Infusions
by Zacks Equity Research
Baxter (BAX) streamlines EMR integration for patients through FDA's approval of Spectrum IQ.
GNC Holdings' Global Prospects Solid, Competition Stiff
by Zacks Equity Research
GNC Holdings (GNC) progresses with deals to boost international presence.
CryoLife (CRY) Stock Gains 9.5% on Impressive Q1 Earnings
by Zacks Equity Research
CryoLife's (CRY) shares gain on growth in all product lines along with strong performance in all geographies in Q1.